Users Stopping Weight-Loss Injections Put On Weight Far More Rapidly Than People Using Diet and Exercise

A recent study reveals that people who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on lost weight far faster than those who end traditional lifestyle regimens.

Research printed in a leading medical journal demonstrates that while overweight individuals often shed a large proportion of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.

"People using such medications should be aware of the potential of fast weight regain when the medication concludes," stated expert Dr. Susan Jebb.

This pace of recovery implies a reversion to starting mass within about 18 months.

Comparing Treatments

The research, which examined dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with conventional dieting.

Scientists point out that people who lose weight through diet and exercise typically see a more gradual creep back—approximately 0.1 kg a month—after stopping.

Explaining the Rapid Rebound

Doctors believe the mode of action of the injections is key to understanding the accelerated rebound.

These medications copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.

"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.

"Withdrawal of this GLP-1 'fix' means hunger is unsuppressed, making excessive eating a significant risk."

A Chronic Issue?

Medical guidelines recommend the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.

Many experts say that, considering the significant potential of relapse, the treatment should be considered life-long.

This view is reinforced by pharmaceutical companies, who state that the findings "emphasize the persistent nature of obesity," akin to managing diseases like high blood pressure.

Patient Experiences

Individuals who have discontinued the jabs report a intense return of hunger.

"I experienced a trigger activating and you become ravenous," recalled a patient.

This challenge is compounded if individuals have not developed permanent lifestyle or habit modifications during therapy.

Significant Use

Survey data show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Use is higher among females than males.
• The middle-aged demographic shows the highest usage rates.
• Many access the medications through private prescriptions rather than public health services.

In conclusion, clinicians caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent solution and maintained weight loss relies on integrated behavioural changes.